Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Characterization of lung cancer patients, their actual treatment and survival : experience of Slovenia
Authors:ID Debevec, Lučka (Author)
ID Debeljak, Andrej (Author)
ID Eržen, Janez (Author)
ID Kovač, Viljem (Author)
ID Kern, Izidor (Author)
Files:.pdf PDF - Presentation file, download (88,13 KB)
MD5: 14B58A155C16549EA07E0E06F05C83A8
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. The aim of the study was to establish characteristics of lung cancer patients diagnosed at the University Clinic of Respiratory and AllergicDiseases Golnik in 1996, their selected and realized therapy, and survival. Methods. The retrospective study comprises 345 patients aged from 37to 90 years (mean 65), 285 males and 60 females. Performance status (Karnofsky): > 80 in 171 patients, 60-80 in 130 and < 60 in 44 patients. Mirroscopically confirmed tumour in 97%: by bronchoscopy 281, transthoracic needle biopsy 23, peripheral lymph nodes biopsy 12, sputum cytology 7, pleural(effusion) cytology 4, distant metastases biopsy 2, mediastinoscopy 1, autopsy 4 patients. Histology and/or cytology: squamous 131, adenocarcinoma 86, large cell 63, small cell 51, non-small cell 1, unclassified 2. Clinical staging of non-small cell lung cancer (NSCLC): stage I 63, stage ll 32, stage IIIA 48, stage IIIB 59, stage IV 77, undeterminable 2 patients. Staging in small cell lung cancer (SCLC): limited disease 24, extended disease 27 patients. Results. The selected primary oncological therapy was changed in 11%. Realized primary therapy: radiotherapy 102 (30%), surgery 77 (23%), chemotherapy 47 (14%), supportive treatment 111 (33%). In resected patients staging was correct in 46%, underestimated in 44%, overestimated in 10%. The overall five-year survival was 7.8% (median 6.2 months) and the five year survival of resected patients was 41.9% (median 33 months). The median survival of irradiated patients was 5.7 months, of supportively treated patients 2.5 months. The survival was significantly different according to theperformance status and stage. (Abstract truncated at 2000 characters)
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2005
Publisher:Association of Radiology and Oncology
Year of publishing:2005
Number of pages:str. 115-121
Numbering:Letn. 39, št. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-18167 New window
UDC:616.2
ISSN on article:1318-2099
COBISS.SI-ID:19765465 New window
Copyright:by Authors
Note:BSDOCID115520;
Publication date in DiRROS:14.02.2024
Views:139
Downloads:33
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:[Slovenske izkušnje pri obavnavi bolnikov s pljučnim rakom, njihove značilnosti in preživetje]
Abstract:Izhodišča. Namen raziskave je bil ugotoviti značilnosti bolnikov s pljučnim rakom, ki so bili diagnosticirani na Kliničnem oddelku za pljučne bolezni in alergijo Golnik v letu 1996. Prav tako smo želeli ugotoviti, kolikšna je bila razlika med izbranim in dejanskim zdravljenjem ter kakšno je bilo preživetje bolnikov. Metode. Retrospektivno smo analizirali dokumentacijo 345 bolnikov, starih od 37 do 90 let (mediana 65), 285 moških in 60 žensk. Telesna zmogljivost (Karnofsky): VVV 80 pri 171 bolnikih, 60-80 pri 130 in ZZZ60 pri 44 bolnikih. Tumor smo mikroskopsko potrdili pri 97% bolnikov, z bronhoskopijopri 281, s transtorakalno igelno biopsijo pri 23, z biopsijo perifernih bezgavk pri 12, s citološko preiskavo sputuma pri 7, s citološko preiskavo plevralnega izliva pri 4, z biopsijo oddaljenih zasevkov pri 2, z mediastinoskopijo pri 1 in z obdukcijo pri 4 bolnikih. Histološko in/ali citološko smo dokazali: pri 131 bolnikih epidermoidni, 86 žlezni, pri 63 velikocelični, pri 51 drobnocelični, pri 1 nedrobnocelični in pri 2 bolnikih neopredeljeni karcinom. Klinični stadij pri nedrobnoceličnem raku je bil v 63 primerih stadij I, v 32 stadij II, v 48 stadij IIIA, v 59 stadij IIIB, v 77 stadij IV, v 2 primerih pa stadija ni bilo mogoče določiti. Pri bolnikih z drobnoceličnim rakom smo ugotovili v 24 primerih omejeno obliko bolezni, v 27 pa razširjeno bolezen. Rezultati. Dejansko onkološko zdravljenje je bilo drugačno kot izbrano zdravljenje pri 11% bolnikov. Primarno smo z obsevanjem zdravili 102 (30%) bolnika, z operacijo 77 (23%), s kemoterapijo 47 (14%) ter s podpornim zdravljenjem 111 (33%) bolnikov. Pri operiranih bolnikih je bilklinični stadij pravilno določen pri 46% bolnikov, prenizko ocenjen pri 44%ter previsoko ocenjen pri 10% bolnikov. (Izvleček prekinjen pri 2000 znakih)


Back